Clinical Trial Update: Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating pemigatinib plus atezolizumab and bevacizumab for advanced cholangiocarcinoma with FGFR2 fusion, currently recruiting at MD …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma

Drugs mentioned

• Avastin (bevacizumab)
• Pemazyre (pemigatinib)
• Tecentriq (atezolizumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Advanced Cholangiocarcinoma, FGFR2 Fusion | Phase 1, Phase 2 | Status: RECRUITING